5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The P2X7 Receptor in Infection and Inflammation.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Adenosine triphosphate (ATP) accumulates at sites of tissue injury and inflammation. Effects of extracellular ATP are mediated by plasma membrane receptors named P2 receptors (P2Rs). The P2R most involved in inflammation and immunity is the P2X7 receptor (P2X7R), expressed by virtually all cells of innate and adaptive immunity. P2X7R mediates NLRP3 inflammasome activation, cytokine and chemokine release, T lymphocyte survival and differentiation, transcription factor activation, and cell death. Ten human P2RX7 gene splice variants and several SNPs that produce complex haplotypes are known. The P2X7R is a potent stimulant of inflammation and immunity and a promoter of cancer cell growth. This makes P2X7R an appealing target for anti-inflammatory and anti-cancer therapy. However, an in-depth knowledge of its structure and of the associated signal transduction mechanisms is needed for an effective therapeutic development.

          Related collections

          Author and article information

          Journal
          Immunity
          Immunity
          Elsevier BV
          1097-4180
          1074-7613
          Jul 18 2017
          : 47
          : 1
          Affiliations
          [1 ] Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy. Electronic address: fdv@unife.it.
          [2 ] School of Pharmacy, University of Camerino, Camerino, Italy.
          [3 ] Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.
          Article
          S1074-7613(17)30280-7
          10.1016/j.immuni.2017.06.020
          28723547
          26777cb9-db38-4d01-b164-deb580525378
          History

          Comments

          Comment on this article